Copyright (c) 2010 Yahoo! Inc. All rights reserved.http://finance.yahoo.com/q/h?s=nbixLatest Financial News for Neurocrine Biosciences, Inc.en-usMon, 21 Dec 2009 13:00:00 Etc/GMThttp://us.news2.yimg.com/us.yimg.com/p/fi/pr/40197.gifhttp://finance.yahoo.com14417http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091221/la28952.html?.v=1Neurocrine Biosciences, Inc. today announced their highly selective vesicular monoamine transporter 2 inhibitor, NBI-98854, will be advanced in clinical development.yahoo_finance/2430049993Mon, 21 Dec 2009 13:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091217/la27746.html?.v=1Neurocrine Biosciences, Inc. today reported that it has entered into a privately negotiated transaction to sell an aggregate of 4,784,689 primary shares of its common stock to affiliates of Venrock at a price of $2.09 per share, raising aggregate gross proceeds to Neurocrine of approximately $10 million.yahoo_finance/1725639798Thu, 17 Dec 2009 11:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091209/la23350.html?.v=1Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from the Tulip PETAL Study , its fifth Phase 2 clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone receptor antagonist, elagolix, in patients with endometriosis.yahoo_finance/518461490Wed, 9 Dec 2009 21:05:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091124/la15456.html?.v=1Neurocrine Biosciences, Inc. announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 21st Annual Piper Jaffray Health Care Conference in New York.yahoo_finance/3724815594Tue, 24 Nov 2009 17:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/q/is?s=nbixyahoo_finance/1863207455Wed, 4 Nov 2009 14:04:34 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091029/nbix10-q.htmlyahoo_finance/2148054505Thu, 29 Oct 2009 20:24:42 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091028/nbix8-k.htmlyahoo_finance/2539119251Wed, 28 Oct 2009 20:16:07 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091028/la99997.html?.v=1Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended September 30, 2009. For the third quarter of 2009, the Company reported a net loss of $8.2 million, or $0.21 per share, compared with a net loss of $17.7 million, or $0.46 per share, for the same period in 2008.yahoo_finance/848332067Wed, 28 Oct 2009 20:05:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/research/earncal/20091028.html?t=nbixyahoo_finance/2730569153Wed, 28 Oct 2009 11:07:39 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091023/la98007.html?.v=1Neurocrine Biosciences, Inc. announced today that the Company will report its third quarter 2009 financial results after the Nasdaq market closes on Wednesday,yahoo_finance/2188349349Fri, 23 Oct 2009 18:05:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091001/nbix8-k.htmlyahoo_finance/3484099590Thu, 1 Oct 2009 20:20:50 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/090915/nbix8-k.htmlyahoo_finance/1235894973Tue, 15 Sep 2009 21:17:55 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/090901/nbix8-k.htmlyahoo_finance/3904941256Tue, 1 Sep 2009 20:06:10 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/090730/nbix10-q.htmlyahoo_finance/789376455Thu, 30 Jul 2009 19:00:27 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/090729/nbix8-k.htmlyahoo_finance/2724566360Wed, 29 Jul 2009 20:41:31 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/090506/nbix10-q.htmlyahoo_finance/218783918Wed, 6 May 2009 18:18:17 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/090505/nbix8-k.htmlyahoo_finance/3879626080Tue, 5 May 2009 20:51:14 Etc/GMThttp://us.rd.yahoo.com/finance/external/mfool/rss/SIG=12l99st9j/*http://www.fool.com/investing/general/2009/04/29/these-5-underdogs-are-no-dogs.aspx?source=eptyholnk303100&logvisit=y&npu=yyahoo_finance/539372497Wed, 29 Apr 2009 19:36:39 Etc/GMThttp://us.rd.yahoo.com/finance/external/tsmpe/rss/SIG=12ag8c89n/*http://www.thestreet.com/p/_yahoo/rmoney/technicalanalysis/10478269.html?cm_ven=YAHOO&cm_cat=PREMIUM&cm_ite=003190yahoo_finance/3297669765Fri, 27 Mar 2009 12:00:59 Etc/GMThttp://us.rd.yahoo.com/finance/external/tsmfe/rss/SIG=133ah1i90/*http://www.thestreet.com/_yahoo/story/10477719/1/neurocrines-elagolix-misses-main-study-goal.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NAyahoo_finance/2896854362Thu, 26 Mar 2009 13:57:19 Etc/GMT